Welcome to our dedicated page for Cerus news (Ticker: CERS), a resource for investors and traders seeking the latest updates and insights on Cerus stock.
Cerus Corporation (CERS) maintains global leadership in blood safety through its INTERCEPT Blood System, a pathogen inactivation platform protecting transfusion medicine worldwide. This dedicated news hub provides investors and healthcare professionals with essential updates on regulatory milestones, clinical advancements, and operational developments.
Access timely reports on FDA clearances, European CE marks, and partnerships with blood centers across 40+ countries. Track progress in platelet and plasma treatment adoption, red blood cell system trials, and international expansion efforts. Our curated news collection ensures you never miss critical updates about this biomedical innovator.
Key coverage areas include quarterly financial results analysis, peer-reviewed study publications, manufacturing capacity expansions, and strategic collaborations with global health organizations. All content is verified through primary sources including company filings and official statements.
Bookmark this page for streamlined access to CERS developments impacting transfusion safety standards. Combine real-time alerts with historical context to understand Cerus' role in combating emerging bloodborne pathogens through cutting-edge nucleic acid targeting technology.
Cerus (Nasdaq: CERS) announced its participation in the 38th International Congress of the International Society of Blood Transfusion (ISBT) in Barcelona, Spain, from June 23 to June 27. The company will host a lunch symposium on June 27, focusing on pathogen inactivation and its benefits for clinical outcomes and randomized studies. Cerus will also present multiple abstracts and posters detailing real-world data on INTERCEPT Platelets and Plasma, Red Blood Cells, and LED Illuminator Programs. Key topics include the safety and efficacy of pathogen-reduced blood products, cold storage of platelet concentrates, and the development of a next-generation illuminator for pathogen inactivation.
Cerus (Nasdaq: CERS) celebrates World Blood Donor Day 2024, highlighting the essential contributions of blood donors worldwide. Established by the World Health Assembly in 2005, this day falls on June 14 each year. The 2024 slogan, '20 years of celebrating giving: thank you blood donors!' acknowledges donors' critical role in ensuring safe blood transfusions globally. Cerus' CEO William 'Obi' Greenman emphasized the importance of donor contributions in maintaining a functional healthcare system. Despite continuous efforts, donor availability remains , particularly in low-income regions. Cerus leverages innovative technology to support donor eligibility and enhance blood availability. To mark the occasion, Cerus hosted a blood drive at its headquarters, promoting community involvement in sustaining blood supplies.
Cerus (Nasdaq: CERS) has announced that its Chief Financial Officer, Kevin Green, will participate in the 21st Annual Craig-Hallum Institutional Investor Conference. The event will take place in Minneapolis on Wednesday, May 29th. This participation is a significant opportunity for Cerus to discuss its financial health and future outlook with key institutional investors.
Cerus (Nasdaq: CERS) reported a 24% increase in product revenue for the first quarter of 2024, reaching $38.4 million. The company also achieved FDA approval for extended shelf life of INTERCEPT Platelet Processing Sets and advanced its LED illuminator program. Cash and cash equivalents were $72.2 million, with a full-year 2024 product revenue guidance range of $172 million to $175 million.
FAQ
What is the current stock price of Cerus (CERS)?
What is the market cap of Cerus (CERS)?
